BioLife Sciences Inc.
BLFE · OTC
2/28/2022 | 8/31/2021 | 5/31/2021 | 2/28/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.32 | -0.30 | 0.00 |
| FCF Yield | -0.00% | -0.06% | -0.22% | -0.19% |
| EV / EBITDA | 0.00 | -147.19 | -147.05 | -430.20 |
| Quality | ||||
| ROIC | -42.58% | 32.93% | 35.73% | 22.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.01 | 0.07 | 0.28 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 503,853.98% | 503,853.98% | 503,853.98% |
| Free Cash Flow Growth | 0.00% | 72.68% | 14.59% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -2.93 | -3.29 | -6.51 |
| Interest Coverage | 0.00 | -16.06 | -10.93 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |